Compare Novartis AG (NVS) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Novartis AG trades at $154.71 (market cap $295.37B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.51. The key difference: Novartis AG pays a 3.07% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none, and Novartis AG is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| NVS | VNQI | |
|---|---|---|
Market Cap | $295.37B | — |
Sector | Health | — |
52-Week High | $168.62 | $50.76 |
52-Week Low | $119.31 | $43.26 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.
The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.77, up 0.46% with a bullish technical signal from moving averages. The ETF provides diversified international real estate exposure across 30+ countries outside the U.S., featuring a low expense ratio and higher dividend yield compared to domestic REIT ETFs. Recent news highlights ongoing comparisons with competing real estate funds, with VNQI's international diversification being a key differentiator.
The outlook for VNQI remains positive given its global real estate diversification benefits and income-oriented profile. Key opportunities include exposure to growing international property markets and attractive dividend yield, while risks involve currency fluctuations, geopolitical uncertainties, and potential underperformance relative to U.S. real estate markets. The ETF's low-cost structure supports long-term total return potential for investors seeking international real estate exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
